|Bid||1.05 x 100|
|Ask||1.40 x 100|
|Day's Range||1.16 - 1.26|
|52 Week Range||0.92 - 2.17|
|PE Ratio (TTM)||-3.43|
|Earnings Date||Aug 1, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1.70|
ArQule, Inc. today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress in Madrid, Spain.
ArQule, Inc. today announced that data from the phase 1/2 trial in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor inhibitor, ARQ 087, will be presented on June 3, 2017 at the 2017 ASCO Annual Meeting in Chicago, Illinois.
Q1 2017 ArQule Inc Earnings Call